5.13

4.65% -0.25

Foghorn Therapeutics Inc (FHTX)

Overview News Price History Option Chain Financials Why FHTX Down? Discussions Forecast

Foghorn Therapeutics Inc stock is traded at $5.13, with a volume of 78,034. It is down -4.65% in the last 24 hours and up +16.33% over the past month. Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Previous Close:

$5.38

Open:

$5.43

24h Volume:

78,034

Relative Volume:

0.50

Market Cap:

$299.19M

Revenue:

$34.16M

Net Income/Loss:

$-98.43M

P/E Ratio:

-2.1923

EPS:

-2.34

Net Cash Flow:

$-119.33M

1W Performance:

-16.31%

1M Performance:

+16.33%

6M Performance:

-30.68%

1Y Performance:

-14.07%

1-Day Range:

$5.09

$5.54

1-Week Range:

$5.09

$6.66

52-Week Range:

$3.86

$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name

Foghorn Therapeutics Inc

Sector

Healthcare (1174)

Industry

Biotechnology (677)

Phone

617-586-3100

Address

500 TECHNOLOGY SQUARE, CAMBRIDGE

Employee

116

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

FHTX's Discussions on Twitter

Compare FHTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FHTX Foghorn Therapeutics Inc	5.1456	299.19M	34.16M	-98.43M	-119.33M	-2.34
VRTX Vertex Pharmaceuticals Inc	480.80	123.34B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	696.80	76.09B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	647.78	39.34B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	251.22	32.49B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	117.21	28.26B	3.30B	-501.07M	1.03B	-2.1146

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Initiated	B. Riley Securities	Buy
Sep-03-24	Initiated	Jefferies	Buy
Aug-19-24	Initiated	Evercore ISI	Outperform
Mar-28-23	Initiated	BofA Securities	Buy
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Nov-22-21	Initiated	H.C. Wainwright	Buy
Nov-17-20	Initiated	Cowen	Outperform
Nov-17-20	Initiated	Goldman	Buy
Nov-17-20	Initiated	Morgan Stanley	Overweight
Nov-17-20	Initiated	Wedbush	Outperform

View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

Feb 17, 2025

Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN

Feb 17, 2025

Feb 12, 2025

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? - MSN

Feb 12, 2025

Layoff Tracker: Q32, Inventiva, Third Harmonic Cut Staff - BioSpace

Feb 12, 2025

Feb 11, 2025

Eagle financial services executive buys $3,200 in stock - MSN

Feb 11, 2025

CENX’s Stock Woes: Up 59.32% in 6 Months, Up 59.32% in Just 5 Days - The InvestChronicle

Feb 11, 2025

Feb 10, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Feb 10, 2025

Harmony Gold Mining Co Ltd ADR (HMY) Stock: A Study of the Market Performance - The News Heater

Feb 10, 2025